Nicotine increases plasminogen activator inhibitor-1 production by human brain endothelial cells via protein kinase C-associated pathway

Stroke

Volumn 30, Issue 3, 1999, Pages 651-655

  Zidovetzki, Raphael ^a   Chen, Peijia ^b   Fisher, Mark ^b   Hofman, Florence M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cerebral ischemia; Endothelium; Nicotine; Plasminogen activator inhibitor 1; Protein kinase C

Indexed keywords

MESSENGER RNA; NICOTINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN KINASE C;

ARTICLE; BRAIN; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; HUMAN CELL; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN SYNTHESIS;

EID: 0032967916     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.30.3.651     Document Type: Article

References (47)

1. Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. BMJ. 1989;298:789-794.
2. Wolf PA, D'Agostino RB, Kannel WB, Bonita R, Belanger AJ. Cigarette smoking as a risk factor for stroke: the Framingham study. JAMA. 1988;259:1025-1029.
3. Miller GJ, Bauer KA, Cooper JA, Rosenberg RD. Activation of the coagulant pathway in cigarette smokers. Thromb Haemost. 1998;79: 549-555.
4. Mast H, Thompson JLP, Lin I-F, Hofmeister C, Hartmann A, Marx P, Mohr JP, Sacco RL. Cigarette smoking as a determinant of high-grade carotid artery stenosis in Hispanic, black, and white patients with stroke or transient ischemic attack. Stroke. 1998;29:908-912.
5. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
6. The NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke. 1997;28: 2109-2118.
7. Hekman CM, Loskutoff DJ. Kinetic analysis of the interactions between plasminogen activator inhibitor 1 and both urokinase and tissue plasminogen activator. Arch Biochem Biophys. 1988;262:199-210.
8. Rydholm H, Boström S. Eriksson E, Risberg B. Complex intracellular signal transduction regulates tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type-1 (PAI-1) synthesis in cultured human umbilical vein endothelium. Scand J Clin Lab Invest. 1995;55: 323-330.
9. Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood. 1987; 69:381-387.
10. Van Mourik JA, Lawrence DA, Loskutoff DJ. Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J Biol Chem. 1984;259:14914-14921.
11. Fisher M, Francis, R. Altered coagulation in cerebral ischemia: platelet, thrombin, and plasma activity. Arch Neurol. 1990;47:1075-1079.
12. Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985;313:1557-1563.
13. Gram J, Jespersen J, Kluft C, Rijken DC. On the usefulness of fibrinolysis variables in the characterization of a risk group for myocardial reinfarction. Acta Med Scand. 1987;221:149-153.
14. Paramo JA, De Boer A, Colucci M, Jonker JJ, Collen D. Plasminogen activator inhibitor (PA-inhibitor)activity in the blood of patients with deep vein thrombosis. Thromb Haemost. 1985;54:725. Letter.
15. Dawson S, Henney A. The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review. Atherosclerosis. 1992;95:105-117.
16. Lupu F, Bergonzelli GE, Heim DA, Cousin E, Genton CY, Bachmann F, Kruithof EKO. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb. 1993;13:1090-1100.
17. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A. 1992;89:6998-7002.
18. Wang L, Kittaka M, Sun N, Schreiber SS, Zlokovic B. Chronic nicotine treatment enhances focal ischemic brain injury and depletes free pool of brain microvascular tissue plasminogen activator in rats. J Cereb Blood Flow Metab. 1997;17:136-146.
19. Hofman FM, Dohadwala MM, Wright AD, Hinton DR, Walker SM. Exogenous Tat protein activates central nervous system-derived endothelial cells. J Neuroimmunol. 1994;54:19-28.
20. Ny T, Sawdey M, Lawrence D, Millan JL, Loskutoff DJ. Cloning and sequence of a cDNA coding for the human beta-migrating endothelial cell-type plasminogen activator inhibitor. Proc Natl Acad Sci U S A. 1986;83:6776-6780.
21. Russell MAH, Wilson C, Patel A, Feyerabend C, Cole PV. Plasma nicotine levels after smoking cigarettes with high, medium and low nicotine yields. BMJ. 1975;2:414-416.
22. Höfer I, Nil R, Wyss F, Bättig K. The contributions of cigarette yield, consumption, inhalation and puffing behavior to the prediction of smoke exposure. J Clin Invest. 1992;70:343-351.
23. Zimmerman M, McGeachie J. The effect of nicotine on aortic endothelium: a quantitative ultrastructural study. Atherosclerosis. 1987;63: 33-41.
24. Talloss JH, Booyse FM. Effects of various agents and physical damage on giant cell formation in bovine aortic endothelial cell cultures. Microvasc Res. 1978;16:51-58.
25. Booyse FM, Osikowicz G, Quarfoot AJ. Effects of chronic oral consumption of nicotine on the rabbit aortic endothelium. Am J Pathol. 1981;102:229-238.
26. Booyse FM, Osikowicz G, Radek J. Effect of nicotine on cultured bovine aortic endothelial cells. Thromb Res. 1981;23:169-185.
27. Bar RS, Boes M, Dake BL, Booth BA, Henley SA, Sandra A. Insulin, insulin-like growth factors, and vascular endothelium. Am J Med. 1988; 85:59-70.
28. Boes M, Dake BL, Bar RS. Interactions of cultured endothelial cells with TGF-β, bFGF, PDGF, and IGF-1. Life Sci. 1991;48:811-821.
29. Beitz JG, Kim I-S, Calabresi P, Fraskelon AR. Human microvascular endothelial cells express receptors for platelet-derived growth factor. Proc Natl Acad Sci U S A. 1991;88:2021-2025.
30. Dupuy E, Bikfalvi A, Rendu F, Toledano SL, Tobelem G. Thrombin mitogenic responses and protein phosphorylation are different in cultured human endothelial cells derived from large and microvessels. Exp Cell Res. 1991;185:363-372.
31. Kollros PR, Konkle BA, Ambarian AP, Henrikson P. Plasminogen activator inhibitor-1 expression by brain microvessel endothelial cells is inhibited by elevated glucose. J Neurochem. 1994;63:903-909.
32. Doctrow SR, Folkman J. Protein kinase C activators suppress stimulation of capillary endothelial cell growth by angiogenic endothelial mitogens. J Cell Biol. 1987;104:679-687.
33. Maher PA. Stimulation of endothelial cell proliferation by vanadate is specific for microvascular endothelial cells. J Cell Physiol. 1992;151: 549-554.
34. Santell L, Levin EG. Cyclic AMP potentiates phorbol ester stimulation of tissue plasminogen activator release and inhibits secretion of plasminogen activator inhibitor-1 from human endothelial cells. J Biol Chem. 1988; 263:16802-16808.
35. Konkle BA, Kollros PR, Kelly MD. Heparin-binding growth factor-1 modulation of plasminogen activator inhibitor-1 expression: interaction with cAMP and protein kinase C-mediated pathways. J Biol Chem. 1990;265:21867-21873.
36. Fukao H, Matsumoto H, Ueshima S, Okada K, Matsuo O. Effects of fibrin on the secretion of plasminogen activator inhibitor-1 from endothelial cells and on protein kinase C. Life Sci. 1995;57:1267-1276.
37. Slivka SR, Loskutoff DJ. Regulation of type I plasminogen activator inhibitor synthesis by protein kinase C and cAMP in bovine aortic endothelial cells. Biochim Biophys Acta. 1991;1094:317-322.
38. Simpson AJ, Gray RS, Moore NR, Booth NA. The effects of chronic smoking on the fibrinolytic potential of plasma and platelets. Br J Haematol. 1997;97:208-211.
39. Margaglione M, Capucci G, d'Addedda M, Colaizzo D, Giuliani N, Vecchione G, Mascolo G, Grandone E, Di Minno G. PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: relation to environmental and genetic determinants. Arterioscler Thromb Vasc Biol. 1998;18:562-567.
40. Hamann GF, Okada Y, Fitridge R, del Zoppo GJ. Microvascular basal lamina antigens disappear during cerebral ischemia and reperfusion. Stroke. 1995;26:2120-2126.
41. Sane DC, Stump DC, Topol EJ, Sigmon KN, Kereiakes DJ, George BS, Mantell SJ, Macy E, Collen D, Califf RM. Correlation between baseline plasminogen activator inhibitor levels and clinical outcome during therapy with tissue plasminogen activator for acute myocardial infarction. Thromb Haemost. 1991;65:275-279.
42. Biemond BJ, Levi M, Coronel R, Jance MJ, ten Cate JW, Pannekoek H. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis: effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody. Circulation. 1995;91:1175-1181.
43. Wagner OF, de Vries C, Hohmann C, Veerman H, Pannekoek H. Interaction between plasminogen activator inhibitor 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). J Clin Invest. 1989;84:647-652.
44. Handt S, Jerome WG, Tietze L, Hantgan RR. Plasminogen activator inhibitor-1 secretion by endothelial cells increases fibrinolytic resistance of an in vitro fibrin clot: evidence for a key role of endothelial cells in thrombolytic resistance. Blood. 1996;87:4204-4213.
45. Benowitz NL. The role of nicotine in smoking-related cardiovascular disease. Preventive Med. 1997;26:412-417.
46. Benowitz NL, Fitzgerald GA, Wilson M, Zhang Q. Nicotine effects on eicosanoid formation and hemostatic function: comparison of transdermal nicotine and cigarette smoking. J Am Coll Cardiol. 1993;22: 1159-1167.
47. Blann AD, Steele C, McCollum CN. The influence of smoking and of oral and transdermal nicotine on blood pressure, and haematology and coagulation indices. Thromb Haemost. 1997;78:1093-1096.